We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Epizyme (EPZM) This Earnings Season?
Read MoreHide Full Article
Epizyme, Inc. is scheduled to report second-quarter 2018 results on Aug 2, before the market opens.
In the last reported quarter, the company delivered a positive earnings surprise of 9.26%. In fact, its track record has been solid with Epizyme surpassing expectations in each of the trailing four quarters, recording an average positive earnings surprise of 8.44%.
Epizyme’s shares have declined 1.9% year to date compared with the industry’s decline of 5.9%.
Let’s see how things are shaping up for this quarter.
Factors Influencing This Quarter
Epizyme has made significant progress with its lead candidate, tazemetostat (an EZH2 inhibitor), for the treatment of multiple types of hematological malignancies and genetically defined solid tumors.
Epizyme is conducting a broad clinical development program for tazemetostat as both a monotherapy and a combination treatment in relapsed/refractory and first-line non-Hodgkin lymphoma (“NHL”).
Based on initial discussions with the FDA during the fourth quarter of 2017, the company believes that it has the opportunity to submit for accelerated approval for tazemetostat as a monotherapy in follicular lymphoma (FL). The company is assessing its timeline for submitting to the FDA a new drug application (NDA) for tazemetostat for FL.
Epizyme has identified a path to submit for accelerated approval of tazemetostat for the treatment of patients with epithelioid sarcoma after discussions with the FDA in 2017. The company expects to file its first NDA seeking accelerated approval of tazemetostat for epithelioid sarcoma in the fourth quarter of 2018.
The company is also exploring tazemetostat to increase the clinical activity of immuno-oncology therapies by combining an anti-PD 1 or PDL-1 agent. Under its collaboration with Roche (RHHBY - Free Report) , the company is evaluating tazemetostat, in combination with anti-PD-L1 cancer immunotherapy, Tecentriq, for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (“DLBCL”) to determine the recommended phase II dose and advance into the expansion portion of the study. The company also plans to commence a combination study of tazemetostat in FL.
During the second quarter of 2018, the company received a setback as the FDA issued a partial clinical hold on the new enrollment of U.S. patients in the company’s ongoing trials for tazemetostat. Following a safety report of a pediatric patient who developed a secondary lymphoma, the FDA issued a partial clinical hold affecting new enrollment of patients with genetically defined solid tumors and hematologic malignancies, while the company updated the informed consent, investigator’s brochure and study protocols. Epizyme plans to complete IND-enabling studies for EZM8266, its G9a inhibitor designed to treat patients with sickle cell disease (SCD), in 2018 and prepare for a Phase 1 study in early 2019.
We expect the investors to focus on the partial hold on tazemetostat along with other updates on the candidate’s studies.
What Does the Zacks Model Unveil?
Our proven model does not conclusively show an earnings beat for Epizyme in the to-be reported quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: Epizyme has an Earnings ESP of -5.95% as the Most Accurate Estimate is pegged at a loss of 56 cents and the Zacks Consensus Estimate is pegged at a loss of 53 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Epizyme currently has a Zacks Rank #2, which increases the predictive power of ESP. However, we need to have a positive Earnings ESP to be confident of an earnings beat.
Note that Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement are best avoided.
Here are some drug/biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Endo International Plc. has an Earnings ESP of +1.37% and currently carries a Zacks Rank #3. The company is scheduled to release second-quarter results on Aug 8.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6% and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
What's in Store for Epizyme (EPZM) This Earnings Season?
Epizyme, Inc. is scheduled to report second-quarter 2018 results on Aug 2, before the market opens.
In the last reported quarter, the company delivered a positive earnings surprise of 9.26%. In fact, its track record has been solid with Epizyme surpassing expectations in each of the trailing four quarters, recording an average positive earnings surprise of 8.44%.
Epizyme’s shares have declined 1.9% year to date compared with the industry’s decline of 5.9%.
Let’s see how things are shaping up for this quarter.
Factors Influencing This Quarter
Epizyme has made significant progress with its lead candidate, tazemetostat (an EZH2 inhibitor), for the treatment of multiple types of hematological malignancies and genetically defined solid tumors.
Epizyme is conducting a broad clinical development program for tazemetostat as both a monotherapy and a combination treatment in relapsed/refractory and first-line non-Hodgkin lymphoma (“NHL”).
Based on initial discussions with the FDA during the fourth quarter of 2017, the company believes that it has the opportunity to submit for accelerated approval for tazemetostat as a monotherapy in follicular lymphoma (FL). The company is assessing its timeline for submitting to the FDA a new drug application (NDA) for tazemetostat for FL.
Epizyme has identified a path to submit for accelerated approval of tazemetostat for the treatment of patients with epithelioid sarcoma after discussions with the FDA in 2017. The company expects to file its first NDA seeking accelerated approval of tazemetostat for epithelioid sarcoma in the fourth quarter of 2018.
The company is also exploring tazemetostat to increase the clinical activity of immuno-oncology therapies by combining an anti-PD 1 or PDL-1 agent. Under its collaboration with Roche (RHHBY - Free Report) , the company is evaluating tazemetostat, in combination with anti-PD-L1 cancer immunotherapy, Tecentriq, for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (“DLBCL”) to determine the recommended phase II dose and advance into the expansion portion of the study. The company also plans to commence a combination study of tazemetostat in FL.
During the second quarter of 2018, the company received a setback as the FDA issued a partial clinical hold on the new enrollment of U.S. patients in the company’s ongoing trials for tazemetostat. Following a safety report of a pediatric patient who developed a secondary lymphoma, the FDA issued a partial clinical hold affecting new enrollment of patients with genetically defined solid tumors and hematologic malignancies, while the company updated the informed consent, investigator’s brochure and study protocols. Epizyme plans to complete IND-enabling studies for EZM8266, its G9a inhibitor designed to treat patients with sickle cell disease (SCD), in 2018 and prepare for a Phase 1 study in early 2019.
We expect the investors to focus on the partial hold on tazemetostat along with other updates on the candidate’s studies.
What Does the Zacks Model Unveil?
Our proven model does not conclusively show an earnings beat for Epizyme in the to-be reported quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: Epizyme has an Earnings ESP of -5.95% as the Most Accurate Estimate is pegged at a loss of 56 cents and the Zacks Consensus Estimate is pegged at a loss of 53 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Epizyme currently has a Zacks Rank #2, which increases the predictive power of ESP. However, we need to have a positive Earnings ESP to be confident of an earnings beat.
Note that Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement are best avoided.
Epizyme, Inc. Price and EPS Surprise
Epizyme, Inc. Price and EPS Surprise | Epizyme, Inc. Quote
Stocks That Warrant a Look
Here are some drug/biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Pacira Pharmaceuticals, Inc. (PCRX - Free Report) has an Earnings ESP of +42.86% and currently carries a Zacks Rank #2. The company is scheduled to release second-quarter report on Aug 2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Endo International Plc. has an Earnings ESP of +1.37% and currently carries a Zacks Rank #3. The company is scheduled to release second-quarter results on Aug 8.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6% and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>